CYTOKINETICS, INCORPORATED Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
CYTOKINETICS, INCORPORATED (CYTK) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $146.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $146.00M, a 3.99% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $140.40M, a 9.18% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $128.60M, a 10.39% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $116.50M, a 121.48% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $146.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $140.40M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $128.60M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $116.50M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $52.60M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $28.90M 10-K · filed 2022-02-25 | |
| 2019-12-31 | $24.80M 10-K · filed 2021-02-26 | |
| 2018-12-31 | $16.20M 10-K · filed 2020-03-04 | |
| 2017-12-31 | -$11.70M 10-K · filed 2019-03-07 | -$11.70K 10-K · filed 2018-03-05 |
| 2016-12-31 | -$2.10M 10-K · filed 2018-03-05 | -$2.20M 10-K · filed 2017-03-06 |
| 2015-12-31 | $13.90M 10-K · filed 2018-03-05 | |
| 2014-12-31 | $1.00M 10-K · filed 2017-03-06 | |
| 2013-12-31 | $13.70M 10-K · filed 2016-03-03 | |
| 2012-12-31 | $21.10M 10-K · filed 2015-03-06 | |
| 2011-12-31 | $18.50M 10-K · filed 2014-03-07 | |
| 2010-12-31 | $15.60M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |